We are live on ! Find out more
SCM

Stonepine Capital Management Portfolio holdings

AUM $250M
1-Year Est. Return 77.6%
This Fund
S&P 500
This Quarter Est. Return
-0.7%
1 Year Est. Return
+77.6%
3 Year Est. Return
+198.76%
5 Year Est. Return
+226.15%
10 Year Est. Return
+1,976.54%
AUM
$187M
AUM Growth
+$19.8M
Cap. Flow
+$29.5M
Cap. Flow %
15.78%
Top 10 Hldgs %
75.87%
Holding
40
New
13
Increased
12
Reduced
4
Closed
10

Top Buys

Rank Stock Value
1
AMRN
Amarin Corp
AMRN
+$21.3M
2
CTIC
CTI BioPharma Corp. (DE) Common Stock
CTIC
+$11.6M
3
BSTC
BioSpecifics Technologies Corp.
BSTC
+$8.57M
4
DOVA
Dova Pharmaceuticals, Inc. Common Stock
DOVA
+$5.5M
5
CFMS
Conformis, Inc. Common Stock
CFMS
+$4.66M

Top Sells

Rank Stock Value
1
ENTA icon
Enanta Pharmaceuticals
ENTA
+$12.8M
2
SCTL
Societal CDMO, Inc. Common Stock
SCTL
+$9.71M
3
CDNA icon
CareDx
CDNA
+$6.75M
4
VCYT icon
Veracyte
VCYT
+$2.85M
5
SBBP
Strongbridge Biopharma plc.
SBBP
+$2.5M

Sector Composition

Rank Sector Weight
1 Healthcare 95.52%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IMDZ
26
DELISTED
Immune Design Corp.
IMDZ
$532K 0.29%
+161,226
New +$571K
SCYX icon
27
SCYNEXIS
SCYX
$36.1M
$509K 0.27%
+4,751
New +$655K
HYPD
28
Hyperion DeFi Inc
HYPD
$36.4M
$365K 0.2%
+499
New +$362K
NGNE icon
29
Neurogene
NGNE
$670M
$287K 0.15%
1,019
-1,006
-50% -$278K
ADMA icon
30
ADMA Biologics
ADMA
$1.98B
– –
-67,647
Closed -$217K
CDNA icon
31
CareDx
CDNA
$1.86B
– –
-920,000
Closed -$6.75M
ENTA icon
32
Enanta Pharmaceuticals
ENTA
$362M
– –
-218,434
Closed -$12.8M
VSTM icon
33
Verastem
VSTM
$533M
– –
-18,750
Closed -$691K
EIGR
34
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
– –
-5,000
Closed -$2.09M
SCTL
35
DELISTED
Societal CDMO, Inc. Common Stock
SCTL
– –
-1,170,878
Closed -$9.71M
FRTX
36
DELISTED
Fresh Tracks Therapeutics, Inc. Common Stock
FRTX
– –
-2,147
Closed -$1.24M
ACER
37
DELISTED
Acer Therapeutics Inc
ACER
– –
-100,000
Closed -$1.39M
SBBP
38
DELISTED
Strongbridge Biopharma plc.
SBBP
– –
-344,282
Closed -$2.5M
NEOS
39
DELISTED
Neos Therapeutics, Inc
NEOS
– –
-140,000
Closed -$1.43M
1
2

Similar funds

BIA
Bigelow Investment Advisors Portland, Maine $250M AUM 19.33% 1-Year Est. Return
ER
EVR Research Richmond, Virginia $250M AUM 41.5% 1-Year Est. Return
FDDB
Fidelity D&D Bancorp Dunmore, Pennsylvania $249M AUM 18.9% 1-Year Est. Return
VM
VPR Management Houston, Texas $250M AUM 34.13% 1-Year Est. Return
PF
Parker Financial Silverdale, Washington $250M AUM 14.69% 1-Year Est. Return
SCM
Step Capital Management Singapore $249M AUM
CWM
Chicago Wealth Management Chicago, Illinois $251M AUM 45.31% 1-Year Est. Return
EWM
Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return

Stonepine Capital Management's Q1 2018 Portfolio in Review

As of Q1 2018, Stonepine Capital Management held 40 positions worth $187M, up 12% from $167M the previous quarter. Its ten largest holdings account for 76% of the portfolio.

Stonepine Capital Management deployed $29.5M of net new capital in Q1 2018, opening 13 new positions and adding to 12 existing holdings. Its largest new stake was Dova Pharmaceuticals, Inc. Common Stock: 184,000 shares worth $4.99M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 98% a quarter earlier.

On the sell side, the largest reduction was Veracyte, an estimated $2.85M trimmed.

  • Stonepine Capital Management's largest Q1 2018 buy was Dova Pharmaceuticals, Inc. Common Stock: 184,000 shares worth $4.99M.
  • Stonepine Capital Management added most to Amarin Corp in Q1 2018, an estimated $21.3M increase.
  • Stonepine Capital Management's biggest Q1 2018 reduction was Veracyte, cutting an estimated $2.85M.
  • Stonepine Capital Management fully exited Enanta Pharmaceuticals in Q1 2018, selling an estimated $12.8M.
  • Stonepine Capital Management's ten largest holdings make up 76% of its $187M portfolio in Q1 2018.
  • Stonepine Capital Management opened 13 new positions and closed 10 in Q1 2018.
  • Stonepine Capital Management's portfolio value rose 12% quarter-over-quarter to $187M.

Based on Stonepine Capital Management's 13F filing for Q1 2018, filed 14 May 2018.